Benralizumab 30mg
| Product Overview | |
| Generic Name | Benralizumab 30mg |
| Brand Name(s) | Fasenra |
| Form | PFS, Subcutaneous injection solutions in vials |
| Strength | 30 mg 1 mL. |
| Therapeutic Class | Humanized monoclonal antibody targeting IL‑5 receptor α |
| ATC Code | R03DX10 |
| Manufacturing & Regulatory | |
| Manufacturer | Astra Zeneca, Cipla, Ranbaxy, others |
| GMP Compliance | WHO-GDP |
| DMF/CEP | Type II |
| COFEPRIS | Registered in Mexico, Batch-specific specific clave unknown |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 25 vials |
| Shelf Life | 24 months |
| Storage | Store refrigerated at 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Approved for maintenance therapy in severe eosinophilic asthma above age 6 and EGPA; not for acute management
